MondayOct 03, 2022 1:38 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Preparing for Ketamine Tech FDA Pre-Investigational New Drug Package

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is collaborating with Premier Consulting to prepare a pre-investigational new drug (“IND”) package and meeting request with the United States Food and Drug Administration (FDA) for SPC-26, the company’s novel topical formulation of ketamine for the treatment of fibromyalgia. The company is planning to pursue a 505(b)(2) regulatory pathway for novel topical formulation of ketamine. According to the company, Premier Consulting will assist with the development of SILO’s nonclinical, clinical, clinical pharmacology, and biopharmaceutics strategy and program to be proposed to the FDA.…

Continue Reading

FridaySep 30, 2022 11:04 am

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of common stock, each at a public offering price of $5.00. Silo Pharma’s common stock began trading on the Nasdaq Capital Market on Sept. 27, 2022, under the symbol SILO. The company secured $5,750,000 million in gross proceeds from the offering, before deducting underwriting discounts and…

Continue Reading

ThursdaySep 29, 2022 11:00 am

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expands Insurance Coverage with Medicare for Ketamine Therapy Patients

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has become one of a few U.S.-based ketamine therapy providers to offer Medicare coverage to patients at eight KWC clinics across the country. Under Medicare, KWC is accepting a limited number of patients for ketamine infusion therapy at Chicago, Denver, Houston, Jacksonville, Minneapolis, Tucson, Salt Lake City and Seattle clinics. In addition, KWC is providing the FDA-approved SPRAVATO(R) esketamine treatment at Houston, Jacksonville and Seattle locations for patients meeting the criteria for insurance coverage. “At Ketamine…

Continue Reading

WednesdaySep 28, 2022 11:36 am

PsychedelicNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Featured in ‘Psychedelics Tonight’ Docuseries

Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, announced it has been featured in a documentary series, which was co-produced by Kyle Buller and Joe Moore of Psychedelics Today in partnership with ALTRD.TV. Entitled Psychedelics Tonight, the docuseries provides information on the history and future potential of several psychedelic compounds including iboga and ibogaine. The first episode of the series aired on Monday, Sept. 26, 2022. “We are excited to see a growing variety of media channels pick up the story of ibogaine, to help educate the public and the…

Continue Reading

TuesdaySep 27, 2022 3:24 pm

PsychedelicNewsBreaks – Awakening of Consciousness to Illuminate Vast Potential of Psychedelic Medicine

The Psychedelic Institute today announced that it is convening the first major psychedelic conference to be held in Los Angeles on Friday, Sept. 30. Slated to take place at the Founder’s Church of Religious Science, the Awakening of Consciousness will offer the public an opportunity to hear, meet and learn from 30 of the world's leading researchers, healers and activists working in the field of psychedelics and plant medicine. The event will feature 18 general session speakers, five panel discussions and seven participatory workshops. Experts will share insight on the vast potential of psychedelic medicine to heal trauma, addiction, depression,…

Continue Reading

TuesdaySep 27, 2022 2:29 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement for the license will provide access to large catalog of compounds that are complementary to Cybin’s preclinical assets and that strengthen the company’s drug-discovery and development platform to build future potential novel drug candidates. The agreement also supports Cybin’s broad intellectual property portfolio of innovative psychedelic-based molecules. According to…

Continue Reading

TuesdaySep 27, 2022 11:39 am

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Uplisting to Nasdaq Capital Market, Pricing of $5M Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. Silo Pharma expects $5,000,000 in gross proceeds from the offering and intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may also be used for acquisitions of complementary businesses, technologies or other assets. As a result of the offering, the company’s…

Continue Reading

MondaySep 26, 2022 10:55 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. According to the update, one application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other, #63/375,305, expands the IP related to the company’s development of TRP-8803. “Tryp is taking an innovative approach to expand treatment alternatives for patients suffering from nociplastic pain and eating disorders who haven’t had success with currently approved drugs,” said Jim Gilligan, chief executive officer of Tryp…

Continue Reading

FridaySep 23, 2022 1:28 pm

PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Closing Under Share Subscription Agreement, Appointment of New CFO

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company today announced that, in connection with its previously disclosed common share subscription agreement with a third-party investor dated Aug. 26, 2022, and the subsequent filing of a shelf prospectus supplement in connection therewith on Sept. 7, 2022, it has closed the second tranche of the first issuance under the subscription agreement. Mydecine also announced the appointment of John Ross as its chief financial officer.…

Continue Reading

ThursdaySep 22, 2022 12:06 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC, VA-CCN Collaborate to Expand Access to SPRAVATO(R) Treatments

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has expanded its partnership with the Veterans Administration Community Care Network (“VA-CCN”) to cover SPRAVATO(R) treatments at select clinics. VA-CCN patients experiencing treatment-resistant depression with prior authorization from the VA-CCN will now have access to treatments at the following KWC clinics: Mesa, Tucson, Phoenix, Denver, Seattle, Reno, Las Vegas, Houston and Dallas. “KWC works every day to provide the best, most effective treatments to those who need them most and our veterans, who suffer from various…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050